Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00566098 · ClinicalTrials.gov registry record · Phase 1
Activated White Blood Cells With ASCT for Newly Diagnosed Multiple Myeloma
A Phase 1 study, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Completed
- Registry status
- Phase 1
- Development phase
- 26
- Enrollment target
NCT00566098 is a Phase 1 study that has completed, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 26 participants.
The verdict
NCT00566098, a Phase 1 study, has completed, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 26 participants
- Enrollment target
Study Summary
RATIONALE: Activating white blood cells in the laboratory may help them kill more cancer cells when they are put back in the body. This may be an effective treatment for patients undergoing a stem cell transplant for multiple myeloma. PURPOSE: This phase I/II trial is studying the side effects of activated white blood cells and to see how well they work in treating patients who are undergoing a stem cell transplant for newly diagnosed stage II or stage III multiple myeloma.
Interventions
- DRUG Melphalan
- BIOLOGICAL MILs
- BIOLOGICAL PCV13
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2007-11 |
| Est. Completion | 2018-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00566098
The ClinicalTrials.gov registry entry for NCT00566098 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Melphalan is the first listed.
NCT00566098 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00566098 about?
NCT00566098 is a clinical study titled "Activated White Blood Cells With ASCT for Newly Diagnosed Multiple Myeloma". RATIONALE: Activating white blood cells in the laboratory may help them kill more cancer cells when they are put back in the body. This may be an effective treatment for patients undergoing a stem cell transplant for multiple myeloma. PURPOSE: This phase I/II trial is studying the side effects of a...
What is the current status of trial NCT00566098?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2007-11. Estimated completion is 2018-10.
What interventions are being tested in trial NCT00566098?
The interventions under investigation include: Melphalan (DRUG), MILs (BIOLOGICAL), PCV13 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00566098?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.